Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors

被引：38

作者：

Amy K. Dickason-Chesterfield ^{[1
]}

Stephanie R. Kidd ^{[1
]}

Steven A. Moore ^{[1
]}

John M. Schaus ^{[1
]}

Bin Liu ^{[1
]}

George G. Nomikos ^{[1
]}

Christian C. Felder ^{[1
]}

机构：

[1] Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis

来源：

Cellular and Molecular Neurobiology | 2006年 / 26卷 / 4期

关键词：

Anandamide; Cannabinoid; Endocannabinoid; Fatty acid amide hydrolase; LY2183240; Marijuana; Transporter;

D O I：

10.1007/s10571-006-9072-6

中图分类号：

学科分类号：

摘要：

1. The mechanism of anandamide uptake and disposal has been an issue of considerable debate in the cannabinoid field. Several compounds have been reported to inhibit anandamide uptake or fatty acid amide hydrolase (FAAH; the primary catabolic enzyme of anandamide) activity with varying degrees of potency and selectivity. We recently reported the first evidence of a binding site involved in the uptake of endocannabinoids that is independent from FAAH. There are no direct comparisons of purported selective inhibitory compounds in common assay conditions measuring anandamide uptake, FAAH activity and binding activity. 2. A subset of compounds reported in the literature were tested in our laboratory under common assay conditions to measure their ability to (a) inhibit [14C]-anandamide uptake in cells containing (RBL-2H3) or cells lacking (HeLa) FAAH, (b) inhibit purified FAAH hydrolytic activity, and (c) inhibit binding to a putative binding site involved in endocannabinoid transport in both RBL and HeLa cell membranes. 3. Under these conditions, nearly all compounds tested inhibited (a) uptake of [14C]-anandamide, (b) enzyme activity in purified FAAH preparations, and (c) radioligand binding of [3H]-LY2183240 in RBL and HeLa plasma membrane preparations. General rank order potency was preserved within the three assays. However, concentration response curves were right-shifted for functional [14C]-anandamide uptake in HeLa (FAAH-/-) cells. 4. A more direct comparison of multiple inhibitors could be made in these three assay systems performed in the same laboratory, revealing more information about the selectivity of these compounds and the relationship between the putative endocannabinoid transport protein and FAAH. At least two separate proteins appear to be involved in uptake and degradation of anandamide. The most potent inhibitory compounds were right-shifted when transport was measured in HeLa (FAAH-/-) cells suggesting a requirement for a direct interaction with the FAAH protein to maintain high affinity binding of anandamide or inhibitors to the putative anandamide transport protein. © 2006 Springer Science+Business Media, Inc.

引用

页码：407 / 423

页数：16

共 50 条

[11]

Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R., Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 5090, pp. 1946-1949, (1992)

[12]

Di M.V., Bifulco M., De Petrocellis L., The endocannabinoid system and its therapeutic exploitation, Nature Reviews Drug Discovery, 3, 9, pp. 771-784, (2004)

[13]

Di Marzo V., De Petrocellis L., Sepe N., Buono A., Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells, Biochem. J., 316, PART 3, pp. 977-984, (1996)

[14]

Marzo D.V., De Petrocellis L., Sugiura T., Waku K., Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells, Biochemical and Biophysical Research Communications, 227, 1, pp. 281-288, (1996)

[15]

Diaz-Laviada I., Ruiz-Llorente L., Signal transduction activated by cannabinoid receptors, Mini-Reviews in Medicinal Chemistry, 5, 7, pp. 619-630, (2005)

[16]

Fegley D., Kathuria S., Mercier R., Li C., Goutopoulos A., Makriyannis A., Piomelli D., Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172, Proceedings of the National Academy of Sciences of the United States of America, 101, 23, pp. 8756-8761, (2004)

[17]

Fernandez J.R., Allison D.B., Rimonabant Sanofi-Synthelabo, Curr. Opin. Invest. Drugs, 5, 4, pp. 430-435, (2004)

[18]

Fowler C.J., Holt S., Nilsson O., Jonsson K.-O., Tiger G., Jacobsson S.O.P., The endocannabinoid signaling system: Pharmacological and therapeutic aspects, Pharmacology Biochemistry and Behavior, 81, 2 SPEC. ISS, pp. 248-262, (2005)

[19]

Fowler C.J., Tiger G., Ligresti A., Lopez-Rodriguez M.L., Di M.V., Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - A difficult issue to handle, European Journal of Pharmacology, 492, 1, pp. 1-11, (2004)

[20]

Giang D.K., Cravatt B.F., Molecular characterization of human and mouse fatty acid amide hydrolases, Proceedings of the National Academy of Sciences of the United States of America, 94, 6, pp. 2238-2242, (1997)

← 1 2 3 4 5 →